Home / Resources / On-Demand Webinar / Getting at the HAART of Precision Dosing: Using PBPK Models to Optimize Dosing of an Antiviral
Getting at the HAART of Precision Dosing: Using PBPK Models to Optimize Dosing of an Antiviral

On-Demand Webinar

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. It is primarily metabolized by CY2B6.

A standard dose of efavirenz has been associated with serious adverse reactions in poor metabolizers (PMs) of CYP2B6, necessitating a reduction in dose. In industrialized countries, clinicians typically genotype patients in order to identify PMs and make the appropriate dose reduction. However, genotyping is not feasible in developing countries. How can we ensure safe dosing for these patients in the absence of this information?

Watch this webinar with Certara’s Dr. Manoranjenni Chetty to learn how she helped develop a PBPK model that was able to predict drug exposure in virtual patients of varying genotypes based solely on input data from a single plasma concentration.

About our Speaker

Manoranjenni Chetty, Project Co-ordinator & Scientific Advisor, Certara. Dr Manoranjenni Chetty is a Project Co-ordinator & Scientific Advisor at Certara. She has extensive experience in Academia, hospital pharmacy, and the pharmaceutical industry. Mano currently holds honorary Professor positions at the University of KwaZulu Natal (South Africa) and the University of Technology Sydney (Australia). She has several publications in her areas of research interest, which include PBPK/PD modelling, inter-individual variability in PK and PD and therapeutic drug monitoring.

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. It is primarily metabolized by CY2B6.

A standard dose of efavirenz has been associated with serious adverse reactions in poor metabolizers (PMs) of CYP2B6, necessitating a reduction in dose. In industrialized countries, clinicians typically genotype patients in order to identify PMs and make the appropriate dose reduction. However, genotyping is not feasible in developing countries. How can we ensure safe dosing for these patients in the absence of this information?

Watch this webinar with Certara’s Dr. Manoranjenni Chetty to learn how she helped develop a PBPK model that was able to predict drug exposure in virtual patients of varying genotypes based solely on input data from a single plasma concentration.

Back to top